

## DAFTAR PUSTAKA

- Amjad, W., Qureshi, W., Farooq, A., Sohail, U., Khatoon, S., Pervaiz, S., Narra, P., Hasan, S. M., Ali, F., Ullah, A., & Guttmann, S. (2017). Gastrointestinal Side Effects of Antiarrhythmic Medications: A Review of Current Literature. *Cureus*, 9(9). <https://doi.org/10.7759/cureus.1646>.
- Andersson, K., Melander, A., Svensson, C., Lind, O., & Nilsson, J. L. G. (2005). Repeat prescriptions: refill adherence in relation to patient and prescriber characteristics, reimbursement level and type of medication. *European Journal of Public Health*, 15(6), 621–626. <https://doi.org/10.1093/eurpub/cki053>.
- Andrade, J., Khairy, P., Dobrev, D., & Nattel, S. (2014). The Clinical Profile and Pathophysiology of Atrial Fibrillation. *Circulation Research*, 114(9), 1453–1468. <https://doi.org/10.1161/CIRCRESAHA.114.303211>.
- Ardiyanti, H. (2024). *Gambaran Penggunaan Obat pada Pasien Atrial Fibrilasi di RSUD Dr. Gunawan Mangunkusumo Tahun 2021-2023*. Universitas Ngudi Waluyo.
- Ashari, M. D. (2023). *Profil Penggunaan Obat-Obat Kardiovaskular pada Pasien Fibrilasi Atrium (Tinjauan Berdasarkan Usia, Jenis Kelamin, Penyakit Penyerta, dan Komplikasi Stroke Iskemik pada Pasien di RSUD Ulin Banjarmasin Tahun 2017-2021)*. Universitas Lambung Mangkurat.
- Astiti, N. K. A., Kusumawati, H. I., & Sutono. (2023). Analisis Data Sistem Rujukan Terintegrasi (Sisrute) di Instalasi Gawat Darurat (IGD) Infeksi RSUP Dr. Sardjito. *Jurnal Manajemen Pelayanan Kesehatan*, 26(1), 1–7.
- Azmi, A. B., Yanni, M., & Efrida, E. (2020). Profil Klinis Pasien Fibrilasi Atrium di RSUP Dr. M. Djamil Padang Periode 1 Januari – 31 Desember 2017. *Jurnal Kesehatan Andalas*, 9(1S), 1. <https://doi.org/10.25077/jka.v9i1S.1148>
- Berliyanti, P. (2022). *Profil Kepatuhan Minum Obat Pasien Hipertensi Menggunakan Metode Proportion of Days Covered (PDC) di RSUD Budhi Asih*. Politeknik Kesehatan Kemenkes Jakarta II.
- BPOM. (2020). *Modul Farmakovigilans untuk Tenaga Kesehatan Profesional Kesehatan Proyek “Ensuring Drug and Food Safety.”* Badan Pengawas Obat dan Makanan.
- Channarayana, V., Marya, R. K., Somasundaram, M., Mitra, D., & Tibrewala, K. D. (2012). Efficacy and tolerability of a  $\beta$ -1 selective  $\beta$  blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study. *BMJ Open*, 2(3), e000683. <https://doi.org/10.1136/bmjopen-2011-000683>.
- Chen, H., Xu, X., Peng, J., Ge, X., Zhang, J., Dong, Q., Jiang, X., & Li, P. (2022). Warfarin Adherence Among Patients with Atrial Fibrillation in Rural Area of Dongyang, China: A Questionnaire-Based Study. *Patient Preference and Adherence*, Volume 16, 2345–2352. <https://doi.org/10.2147/PPA.S374808>
- Cheng, J. W. M., & Rybak, I. (2010). Use of Digoxin for Heart Failure and Atrial Fibrillation in Elderly Patients. *The American Journal of Geriatric Pharmacotherapy*, 8(5), 419–427. <https://doi.org/10.1016/j.amjopharm.2010.10.001>.

- Choi, J.-I., Park, Y. M., Oh, Y.-S., Kim, J.-B., Han, S., Park, J.-S., On, Y. K., Choi, K.-J., Hwang, G.-S., Lee, M.-H., Shin, D.-G., Kim, N.-H., Kim, D.-K., Namgung, J., Kim, D.-H., Park, H.-W., Park, H.-C., Choi, E.-K., Rhee, K. S., ... Kim, Y.-H. (2024). Efficacy and Safety of Once-Daily Carvedilol in Patients with Atrial Fibrillation: A Randomized, Double-Blind, Placebo-Controlled Trial. *Heart Rhythm*. <https://doi.org/10.1016/j.hrthm.2024.04.057>.
- Crader, M., Johns, T., & Arnold, J. K. (2023). Warfarin Drug Interactions. *StatPearls [Internet]*.
- Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008). Medication Compliance and Persistence: Terminology and Definitions. *Value in Health*, *11*(1), 44–47. <https://doi.org/10.1111/j.1524-4733.2007.00213.x>.
- Dagres, N., Lewalter, T., Lip, G. Y. H., Pison, L., Proclemer, A., & Blomström-Lundqvist, C. (2013). Current Practice of Antiarrhythmic Drug Therapy for Prevention of Atrial Fibrillation in Europe: The European Heart Rhythm Association Survey. *EP Europace*, *15*(4), 478–481. <https://doi.org/10.1093/europace/eut063>.
- Depkes RI. (2009). *Sistem Kesehatan Nasional*. Departemen Kesehatan RI.
- Desai, D. S., & Hajouli, S. (2023). Arrhythmias. In *StatPearls [Internet]*. StatPearls Publishing.
- Dipiro, J. T., Talbert, R. L., Yee, G. R., Wells, B. G., & Posey, L. M. (2017). *Pharmacotherapy: A Pathophysiologic Approach* (10th ed.). McGraw-Hill Education.
- Dorian, P., & Angaran, P. (2014).  $\beta$ -Blockers and Atrial Fibrillation: Hypertension and Other Medical Conditions Influencing Their Use. *Canadian Journal of Cardiology*, *30*(5), S38–S41. <https://doi.org/10.1016/j.cjca.2013.09.029>.
- Dorian, P., & Angaran, P. (2023). Beta-Blockers and Digoxin in Atrial Fibrillation: Back to the Future. *Canadian Journal of Cardiology*, *39*(11), 1594–1597. <https://doi.org/10.1016/j.cjca.2023.07.013>
- Effendi. (2017). Tatalaksana Fibrilasi Atrium. *Cermin Dunia Kedokteran (CDK) Journal*, *44*(2).
- Elezi, S., Qerkini, G., Bujupi, L., Shabani, D., & Bajraktari, G. (2010). Management and comorbidities of atrial fibrillation in patients admitted in cardiology service in Kosovo—a single-center study. *Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology*, 36–40. <https://doi.org/10.5152/akd.2010.008>.
- Elkerdawy, N. M. H., Ahmed, N. G., & Khorais, A. M. (2022). Knowledge and Adherence to Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. *Egyptian Journal of Health Care*, *14*(1), 72–87.
- Gažová, A., Leddy, J. J., Rexová, M., Hlivák, P., Hatala, R., & Kyselovič, J. (2019). Predictive value of CHA<sub>2</sub>DS<sub>2</sub>-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). *Medicine*, *98*(31), e16560. <https://doi.org/10.1097/MD.00000000000016560>.

- Gillis, A. M., Verma, A., Talajic, M., Nattel, S., & Dorian, P. (2011). Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management. *Canadian Journal of Cardiology*, 27(1), 47–59. <https://doi.org/10.1016/j.cjca.2010.11.001>.
- Irmansyah, Y. A., & Pintaningrum, Y. (2020). Karakteristik Pasien Atrial Fibrilasi Pada Pasien Rawat Jalan Rumah Sakit Umum Daerah Provinsi Nusa Tenggara Barat Periode Januari 2015 Hingga Januari 2016. *Jurnal Kedokteran*, 9(3), 229–237.
- Istanto, T. A. (2009). *Pola Penggunaan Obat pada Pasien Fibrilasi Atrium yang Menjalani Rawat Inap di Rumkital Dr. Ramelan Surabaya*. Universitas Surabaya.
- Jadhav, U., Nair, T., Bansal, S., & Ray, S. (2021). Efficacy and Safety of Bisoprolol Compared to Other Selective Beta-1 Blockers in The Treatment of Hypertension: a Systematic Review and Meta-analysis of Randomized Parallel Clinical Trials. *European Heart Journal*, 42(Supplement\_1). <https://doi.org/10.1093/eurheartj/ehab724.2363>.
- Kardas, P., Lewek, P., & Matyjaszczyk, M. (2013). Determinants of patient adherence: a review of systematic reviews. *Frontiers in Pharmacology*, 4. <https://doi.org/10.3389/fphar.2013.00091>.
- Kemendes. (2011). *Modul Penggunaan Obat Rasional*. Kementerian Kesehatan Republik Indonesia.
- Kemendes. (2016). *Buku Panduan Jaminan Kesehatan (JKN) bagi Populasi Kunci*. Kementerian Kesehatan RI.
- Khairunnisa, & Ananda, M. R. (2023). Penggunaan Obat pada Pasien Geriatri Rawat Jalan Rumah Sakit Universitas Sumatera Utara. *Majalah Farmasi Dan Farmakologi*, 6–10.
- Ko, D., Rahman, F., Schnabel, R. B., Yin, X., Benjamin, E. J., & Christophersen, I. E. (2016). Atrial Fibrillation in Women: Epidemiology, Pathophysiology, Presentation, and Prognosis. *Nature Reviews Cardiology*, 13(6), 321–332. <https://doi.org/10.1038/nrcardio.2016.45>.
- Krisnayanti, M. W. (2019). Penggunaan Antikoagulan Oral Baru pada Fibrilasi Atrium. *Jurnal Farmasi Udayana*, 8(1), 1–6. <https://doi.org/10.24843/JFU.2019.v08.i01.p01>.
- Kuhlkamp, V., Bosch, R., Mewis, C., & Seipel, L. (2002). Use of Beta-Blockers in Atrial Fibrillation. *American Journal of Cardiovascular Drugs*, 2(1), 37–42. <https://doi.org/10.2165/00129784-200202010-00005>.
- Lemeshow, S., Hosmer Jr., D. W., Klar, J., & Lwanga, S. K. (1990). *Adequacy of Sample Size in Health Studies*. John Wiley & Sons Ltd.
- Liu, B., Zhang, R., Zhang, A., Wang, G., Xu, J., Zhang, Y., Liu, Y., & Hao, P. (2023). Effectiveness and Safety of Four Different Beta-blockers in Patients with Chronic Heart Failure. *MedComm*, 4(1). <https://doi.org/10.1002/mco2.199>.
- Medford, A. R. (2012). A 54 Year-Old Man with a Chronic Cough — Chronic Cough: Don't Forget Drug-Induced Causes. *Primary Care Respiratory Journal*, 21(3), 347–348. <https://doi.org/10.4104/pcrj.2012.00078>.

- Nabar, A., & Pathan, I. (2016). Pathophysiology of Atrial Fibrillation -Current Concepts. *Supplement to Journal of The Association of Physicians of India*, 11–15.
- Naser, N., Dilic, M., Durak, A., Kulic, M., Pepic, E., Smajic, E., & Kusljugic, Z. (2017). The Impact of Risk Factors and Comorbidities on The Incidence of Atrial Fibrillation. *Materia Socio Medica*, 29(4), 231. <https://doi.org/10.5455/msm.2017.29.231-236>.
- NCBI. (2023). *Overview: Atrial fibrillation*. Institute for Quality and Efficiency in Health Care.
- Nesheiwat, Z., Goyal, A., & Jagtap, M. (2023). Atrial Fibrillation. In *StatPearls [Internet]*. StatPearls Publishing.
- Nursalim, A., & Setiabudi, E. (2012). Efektivitas Antikoagulan Baru Dibandingkan dengan Warfarin dalam Mencegah Stroke pada Pasien Atrial Fibrilasi. *J Indom Med Assoe*, 62(10), 407–411.
- Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., O’Gara, P. T., Rigolin, V. H., Sundt, T. M., Thompson, A., & Toly, C. (2021). 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, 143(5). <https://doi.org/10.1161/CIR.0000000000000923>.
- Pacleb, A., Lowres, N., Randall, S., Neubeck, L., & Gallagher, R. (2020). Adherence to Cardiac Medications in Patients With Atrial Fibrillation: A Pilot Study. *Heart, Lung and Circulation*, 29(7), e131–e139. <https://doi.org/10.1016/j.hlc.2019.11.012>.
- PERKI. (2014). *Pedoman Tatalaksana Fibrilasi Atrium* (1st ed.). Centra Communications.
- PERKI. (2019). *Pedoman Fibrilasi Atrium Non-valvular PERKI 2019*. Persatuan Dokter Spesialis Kardiologi.
- PERKI. (2023). *Pedoman Tatalaksana Gagal Jantung* (Edisi Ketiga). Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.
- Prieto-Merino, D., Mulick, A., Armstrong, C., Hoult, H., Fawcett, S., Eliasson, L., & Clifford, S. (2021). Estimating proportion of days covered (PDC) using real-world online medicine suppliers’ datasets. *Journal of Pharmaceutical Policy and Practice*, 14(1), 113. <https://doi.org/10.1186/s40545-021-00385-w>.
- Račkauskas, G., Zabiela, V., Marinskis, G., Baranauskas, A., Balkutė, D., Alunderytė, J., Puodžiūkytas, A., Kazakevičius, T., Kviesulaitis, V., & Aidietis, A. (2017). Evaluation of atrial fibrillation management and cardiovascular risk profile in atrial fibrillation patients: A cross-sectional survey. *Medicina*, 53(1), 19–25. <https://doi.org/10.1016/j.medici.2017.01.005>.
- Renoux, C., Patenaude, V., & Suissa, S. (2014). Incidence, Mortality, and Sex Differences of Non-Valvular Atrial Fibrillation: A Population-Based Study. *Journal of the American Heart Association*, 3(6). <https://doi.org/10.1161/JAHA.114.001402>.

- Rolls, C. A., Obamiro, K. O., Chalmers, L., & Bereznicki, L. R. E. (2017). The Relationship Between Knowledge, Health Literacy, and Adherence Among Patients Taking Oral Anticoagulants for Stroke Thromboprophylaxis in Atrial Fibrillation. *Cardiovascular Therapeutics*, 35(6). <https://doi.org/10.1111/1755-5922.12304>.
- Roveny. (2015). Antikoagulan untuk Stroke Iskemik Kardioemboli. *Cermin Dunia Kedokteran*, 42(5), 345–349.
- Safrina, U. (2014). *Studi Penggunaan Antikoagulan pada Pasien Penyakit Atrial Fibrilasi (Penelitian di Instalasi Rawat Inap Jantung dan Pembuluh Darah RSUD Dr. Soetomo Surabaya)*. Universitas Airlangga.
- Salmasi, S., Loewen, P. S., Tandun, R., Andrade, J. G., & De Vera, M. A. (2020). Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. *BMJ Open*, 10(4), e034778. <https://doi.org/10.1136/bmjopen-2019-034778>.
- Shafeeq, H., & Tran, T. H. (2014). New Oral Anticoagulants For Atrial Fibrillation: Are They Worth the Risk? *P & T: A Peer-Reviewed Journal for Formulary Management*, 39(1), 54–64.
- Siddiqi, H. K., Vinayagamoorthy, M., Gencer, B., Ng, C., Pester, J., Cook, N. R., Lee, I.-M., Buring, J., Manson, J. E., & Albert, C. M. (2022). Sex Differences in Atrial Fibrillation Risk. *JAMA Cardiology*, 7(10), 1027. <https://doi.org/10.1001/jamacardio.2022.2825>.
- Sidik, A. B. M. (2020). *Studi Penggunaan Obat Amiodaron dan Digoksin pada Pasien Atrial Fibrilasi (Penelitian di Rumah Sakit Umum Dr. Soetomo Surabaya)*. Universitas Airlangga.
- Undas, A., Drabik, L., & Potpara, T. (2020). Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. *Polish Archives of Internal Medicine*. <https://doi.org/10.20452/pamw.15136>.
- Wasmer, K., Eckardt, L., & Breithardt, G. (2017). Predisposing Factors for Atrial Fibrillation in The Elderly. *Journal of Geriatric Cardiology: JGC*, 14(3), 179–184. <https://doi.org/10.11909/j.issn.1671-5411.2017.03.010>.